The market taxonomy by type differentiates Neurological Disorder Drugs into small‑molecule, biologic, peptide, and emerging gene‑therapy categories, each with distinct cost structures and adoption curves. Small‑molecule agents remain the backbone of symptomatic treatment, representing roughly 55 % of total spend; their manufacturing scalability and oral administration drive broad market penetration across Alzheimer’s, Parkinson’s, and epilepsy indications. Biologics, chiefly monoclonal antibodies and recombinant proteins, account for about 30 % of revenue, reflecting premium pricing for disease‑modifying therapies in multiple sclerosis and certain rare neurodegenerative disorders. Peptide‑based drugs, including neuropeptide analogues for migraine prophylaxis, contribute near 8 %, benefiting from targeted delivery but limited by injection requirements. Gene‑therapy and RNA‑interference platforms, still nascent, occupy roughly 4 % of the market but exhibit compound annual growth rates exceeding 40 %, indicating a disruptive potential that could re‑balance the type distribution over the next decade. The remaining 3 % comprises hybrid formulations and repurposed agents, which sustain niche demand without materially shifting the overall market size. This type‑level segmentation clarifies where R&D capital is concentrated and how pricing dynamics shape the Neurological Disorder Drugs market.
